Epilepsy
| Epilepsy Research Benchmarks |
|---|
| Highlights |
|---|
| Judith Hoyer Lecture on Epilepsy |
| Resource Links |
|---|
| Anticonvulsant Screening Program (ASP) NIH RePORTER is an electronic tool that allows users to search a repository of NIH-funded research projects and access publications and patents resulting from NIH funding. |
| Contacts |
|---|
| Brandy Fureman, Ph.D. Program Director, Channels Synapses & Circuits Cluster furemanb@mail.nih.gov Deborah Hirtz, M.D. Randall Stewart, Ph.D. Vicky Whittemore, Ph.D. |
|
Epilepsy Benchmark IIIC Benchmark Area III. Create and implement new therapies free of side effects that are aimed at the cessation of seizures in patients with epilepsy. C. Specific Benchmark: Define the extent of diffuse seizure suppressing systems that may be dysfunctional in multifocal epilepsies. Define methods of activating these systems to ameliorate or even suppress seizures. |
2005 Report submitted by Benchmark Steward(s):
Brian Litt, M.D. (University of Pennsylvania)
Background of the benchmark goal:
Multifocal epilepsies and conditions in which seizures spread rapidly throughout the brain (symptomatic generalized epilepsies)
are among the most difficult epileptic disorders to treat. This is because they are often refractory to medical therapy and
not treatable by resective epilepsy surgery. For these reasons, there is great interest in understanding pathways regulating
seizure generation and spread that may be dysfunctional in these disorders, and in modulating their activity to suppress seizures
that arise from multiple foci or networks regulating seizure spread.
Current status of the field:
Current research in the field is focused on several pathways, including those centered on the striato-nigral, anterior, central
and subthalamic regions for seizure spread. Other investigation is focused on connected regions, including periaqueductal
gray. Currently, these areas are being investigated in animal models of epilepsy with array recordings from these regions
during acute and less commonly spontaneous seizures. Equally important as these ongoing studies is the great interest in
devices to treat medically refractory epilepsy, and the need for research to support this task. This includes renewed interest
in mapping epileptic networks, understanding seizure generation and spread, developing quantitative tools to predict seizures
and guide intervention strategies, and methods to translate animal work in this area rapidly into human therapy. While multifocal
and symptomatic generalized epilepsies present specific challenges, specifically that seizures spread so rapidly that focal
onset may vary or not be indentifiable by current methods, they have much in common with simpler cases which are the subject
of clinical trials of implantable devices. Functional imaging, electrophysiological and modeling studies in patients with
multifocal and symptomatic generalized epilepsies are getting underway. These include individuals with cortical dysplasia,
tuberous sclerosis and genetic causes of multifocal and symptomatic generalized epilepsies (band and multinodular periiventricular
heterotopias, lissencephaly, schizencephaly, hypothalamic hamartoma, and similar disorders). This is also interest in new
imaging tools to study non-invasive, real-time imaging correlates of seizure generation and spread. It is hoped that these
types of studies may help identify central regions that are and can be activated to suppress poorly localized, multifocal
or refractory seizures. It is clear from ongoing clinical research that even surgical therapy can be very effective in this
patient population, with proper electrophysiologic evidence of discrete seizure onset.
Activities update:
Top priorities for next 5-10 years:
Roadblocks to progress:
References:
Last updated January 12, 2010